Jms Bartlett

Summary

Affiliation: University of Edinburgh
Country: UK

Publications

  1. doi request reprint Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma
    Dana Faratian
    Division of Pathology and Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Edinburgh, UK
    Histopathology 54:254-7. 2009
  2. pmc Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction
    M R Baneshi
    Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK
    Br J Cancer 102:1503-10. 2010
  3. pmc Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experiments
    Robert R Kitchen
    Applied Bioinformatics of Cancer Group, Breakthrough Breast Cancer Research Unit, Institute of Genetics and Molecular Medicine, Crewe Road South, Edinburgh, Edinburgh, EH4 2XR, UK
    BMC Genomics 12:589. 2011
  4. pmc Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer
    Sampoorna Satheesha
    Leeds Institute of Molecular Medicine, St, James s University Hospital, Leeds University, UK
    Mol Cancer 10:19. 2011
  5. pmc Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles
    Robert R Kitchen
    School of Physics, University of Edinburgh, 10 Crichton Street, Edinburgh, EH8 9AB, UK
    BMC Genomics 11:134. 2010
  6. pmc External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK
    J Clin Pathol 60:816-9. 2007
  7. ncbi request reprint A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, UK
    Histopathology 56:297-304. 2010
  8. ncbi request reprint Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer
    M Spears
    Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, Scotland
    Biomark Med 2:397-407. 2008
  9. pmc Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Carrington Crescent, Edinburgh EH4 2XU, UK
    Breast Cancer Res 12:R47. 2010
  10. doi request reprint Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions
    John M S Bartlett
    Endocrine Cancer Group and Edinburgh Breakthrough Breast Cancer Laboratory, Edinburgh University, Western General Hospital, Crewe Road South, Edinburgh, UK
    Clin Breast Cancer 10:S86-95. 2010

Collaborators

Detail Information

Publications45

  1. doi request reprint Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma
    Dana Faratian
    Division of Pathology and Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Edinburgh, UK
    Histopathology 54:254-7. 2009
    ..The aim was to describe the pattern and frequency of membranous/cytoplasmic Ki67 in a cohort of invasive breast carcinomas, and their associations with grade, HER2 amplification and oestrogen receptor (ER) expression...
  2. pmc Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction
    M R Baneshi
    Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK
    Br J Cancer 102:1503-10. 2010
    ..A particular goal was to enable the discrimination of patients with a very low risk of recurrence...
  3. pmc Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experiments
    Robert R Kitchen
    Applied Bioinformatics of Cancer Group, Breakthrough Breast Cancer Research Unit, Institute of Genetics and Molecular Medicine, Crewe Road South, Edinburgh, Edinburgh, EH4 2XR, UK
    BMC Genomics 12:589. 2011
    ....
  4. pmc Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer
    Sampoorna Satheesha
    Leeds Institute of Molecular Medicine, St, James s University Hospital, Leeds University, UK
    Mol Cancer 10:19. 2011
    ..In an alternative approach we estimated eIF4E activity, a key effector of mTOR function, and tested the hypothesis that eIF4E activity predicts sensitivity to mTOR inhibition in cell lines and in breast tumours...
  5. pmc Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles
    Robert R Kitchen
    School of Physics, University of Edinburgh, 10 Crichton Street, Edinburgh, EH8 9AB, UK
    BMC Genomics 11:134. 2010
    ....
  6. pmc External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK
    J Clin Pathol 60:816-9. 2007
    ..However, until recently, no provision was available for HER2 fluorescence in situ hybridisation (FISH) testing. A pilot scheme was set up to review the performance of FISH testing in clinical diagnostic laboratories...
  7. ncbi request reprint A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, UK
    Histopathology 56:297-304. 2010
    ..To assess a new HER2 fluorescence in situ hybridization (FISH) test and report on multicentre intrasite and intersite variation...
  8. ncbi request reprint Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer
    M Spears
    Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, Scotland
    Biomark Med 2:397-407. 2008
    ..Here we review the human epidermal growth factor receptor family of proteins and their potential predictive or prognostic role in early breast cancer...
  9. pmc Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Carrington Crescent, Edinburgh EH4 2XU, UK
    Breast Cancer Res 12:R47. 2010
    ..We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up...
  10. doi request reprint Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions
    John M S Bartlett
    Endocrine Cancer Group and Edinburgh Breakthrough Breast Cancer Laboratory, Edinburgh University, Western General Hospital, Crewe Road South, Edinburgh, UK
    Clin Breast Cancer 10:S86-95. 2010
    ..Herein, gaps in current knowledge are highlighted and suggestions for future research directions given that may facilitate biomarker development in partnership with current drug development...
  11. doi request reprint Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh University, Edinburgh, UK
    Lancet Oncol 11:266-74. 2010
    ..We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A...
  12. ncbi request reprint Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy
    John M S Bartlett
    Endocrine Cancer Research Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom
    J Clin Oncol 25:4423-30. 2007
    ..We tested interactions between ER and HER-2 to determine if they may modulate breast cancer nodal metastasis and proliferation...
  13. pmc Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Rd South, Edinburgh, EH4 2XR, United Kingdom
    J Clin Oncol 29:1531-8. 2011
    ....
  14. doi request reprint Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial
    John M S Bartlett
    Endocrine Cancer Research Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK
    J Clin Oncol 26:5027-35. 2008
    ..We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy...
  15. ncbi request reprint Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?
    Sian Tovey
    Endocrine Cancer Group, Section of Surgical and Translational Research, Glasgow University, United Kingdom
    Clin Cancer Res 11:4835-42. 2005
    ..We previously reported reduced survival in patients overexpressing HER1, HER2, and HER3. We now show that both HER1-3 and PR status predicts for early relapse in estrogen receptor (ER)-positive tamoxifen-treated breast cancer patients...
  16. ncbi request reprint Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer
    Vicky S Sabine
    Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, UK
    Breast Cancer Res Treat 122:419-28. 2010
    ....
  17. pmc Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling
    Sian M Tovey
    Endocrine Cancer Group, Division of Cancer Sciences and Molecular Biology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
    Breast Cancer Res 6:R246-51. 2004
    ..In this study, bromodeoxyuridine (BrdU)-derived proliferation indices are correlated with clinical outcome and HER1-4 status for further clarification of the differing roles for the HER family at a biological level...
  18. ncbi request reprint Bad expression predicts outcome in patients treated with tamoxifen
    Elizabeth Cannings
    Endocrine Cancer Group, Glasgow Royal Infirmary, University Department of Surgery, Glasgow, Scotland, UK
    Breast Cancer Res Treat 102:173-9. 2007
    ..The present study was carried out to test the hypothesis that disruption of apoptosis in breast cancer, via Akt activation, is linked with hormone resistance...
  19. ncbi request reprint Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients
    Tove Kirkegaard
    Endocrine Cancer Group, Section of Surgical and Translational Research, Glasgow University, Glasgow Royal Infirmary, Glasgow, United Kingdom
    Clin Cancer Res 13:1405-11. 2007
    ..The present study was carried out to test the hypothesis that AIB1 protein expression and/or gene amplification mediates tamoxifen resistance in breast cancer...
  20. ncbi request reprint AKT activation predicts outcome in breast cancer patients treated with tamoxifen
    Tove Kirkegaard
    Endocrine Cancer Group, Division of Cancer Sciences and Molecular Pathology, Department of Surgery, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
    J Pathol 207:139-46. 2005
    ....
  21. doi request reprint Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience
    Dana Faratian
    Division of Pathology, Edinburgh Cancer Research Centre, Edinburgh, Scotland
    Histopathology 55:587-93. 2009
    ..The aim of this study was to investigate the potential of image analysis for accurate and reproducible quantitative evaluation of biomarkers...
  22. ncbi request reprint Hormonal therapy for postmenopausal breast cancer: the science of sequencing
    William R Miller
    Breast Unit, Western General Hospital, Paderewski Building, Edinburgh, EH4 2XU, UK
    Breast Cancer Res Treat 103:149-60. 2007
    ..Prospective, randomized clinical trials are needed to determine the best use of therapies in particular settings, taking into account the spectrum of molecular phenotypes in different tumours...
  23. ncbi request reprint Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy
    John M S Bartlett
    Section of Surgical and Translational Research, Division of Cancer, Department of Surgery, Sciences and Molecular Pathology, Endocrine Cancer Group, Glasgow Royal Infirmary, University of Glasgow, Glasgow, Scotland
    Am J Pharmacogenomics 5:303-15. 2005
    ..This approach serves as a paradigm for the future development of pharmacodiagnostic tests in oncology...
  24. ncbi request reprint HER2 FISH in breast cancer
    John M S Bartlett
    Division of Cancer and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Scotland, UK
    Methods Mol Med 97:89-101. 2004
  25. ncbi request reprint The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer
    Joanne Edwards
    Endocrine Cancer Group, Division of Cancer Sciences and Molecular Pathology, Glasgow Royal Infirmary, Glasgow, United Kingdom
    Clin Cancer Res 12:123-30. 2006
    ..Breast cancer studies show that these receptors should be investigated as a family. The current study investigates expression of HER1-HER4 and EGFRvIII in matched hormone-sensitive and hormone-refractory prostate tumors...
  26. doi request reprint Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, Scotland, UK
    Am J Clin Pathol 130:920-6. 2008
    ..We recommend that all breast cancer cases with a HER2 copy number of 2 to 7 determined by single-color in situ hybridization should also be analyzed for chromosome 17 to obtain a more accurate diagnosis of HER2 amplification...
  27. doi request reprint Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers
    Tove Kirkegaard
    Endocrine Cancer Research Group, Division of Cancer Sciences and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, Scotland
    Am J Clin Pathol 129:735-43. 2008
    ..The data presented herein show TACE expression in endocrine cancers and further support a role for TACE in breast cancer apoptosis...
  28. pmc HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4
    Sian M Tovey
    Endocrine Cancer Group, Section of Surgical and Translational Research, Glasgow University, UK
    Breast Cancer Res 8:R19. 2006
    ..We have therefore compared the staining patterns of antibodies against its intracellular and extracellular domains using tissue microarray technology...
  29. doi request reprint Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients
    Liane M McGlynn
    Endocrine Cancer Group, Division of Cancer Studies and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom
    Clin Cancer Res 15:1487-95. 2009
    ....
  30. ncbi request reprint The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways
    Joanne Edwards
    Section of Surgical and Translational Research, Division of Cancer and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, Scotland, UK
    BJU Int 95:1327-35. 2005
  31. doi request reprint Human epidermal growth factor receptor dimerization analysis in breast cancer diagnosis: potential for improving testing accuracy and treatment selection
    Melanie Spears
    Edinburgh Breakthrough Breast Cancer Research Unit, Endocrine Cancer Research Group, Western General Hospital, Edinburgh, UK
    Mol Diagn Ther 13:359-65. 2009
    ..Here, we review the methods by which HER dimerization can be explored and the potential that this has in the treatment of breast cancer...
  32. doi request reprint Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up
    Jeremy St J Thomas
    Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK
    Histopathology 55:724-31. 2009
    ....
  33. doi request reprint External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, Scotland
    Am J Clin Pathol 131:106-11. 2009
    ..Participation in external quality assurance schemes is a valuable mechanism for demonstrating and acquiring consistency for HER2 testing by in situ hybridization. Poor performance can be corrected via assistance and advice...
  34. ncbi request reprint The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor
    Joanne Edwards
    Section of Surgical and Translational Research, Division of Cancer and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, Scotland, UK
    BJU Int 95:1320-6. 2005
  35. ncbi request reprint Fluorescence in situ hybridization: technical overview
    John M S Bartlett
    Division of Cancer and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Scotland, UK
    Methods Mol Med 97:77-87. 2004
  36. ncbi request reprint The role of c-Jun and c-Fos expression in androgen-independent prostate cancer
    Joanne Edwards
    Endocrine Cancer Group, Section of Surgical and Translational Research, University of Glasgow, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK
    J Pathol 204:153-8. 2004
    ..However, PKC appears to promote the development of AIPC independently of c-Jun activation via an as yet unexplained mechanism...
  37. ncbi request reprint Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization
    Jorma Isola
    Laboratory of Cancer Genetics, Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
    Clin Cancer Res 10:4793-8. 2004
    ..We compared detection of HER-2/neu amplification by CISH with a Food and Drug Administration-approved two-color FISH test in an interlaboratory setting...
  38. ncbi request reprint Gene amplifications associated with the development of hormone-resistant prostate cancer
    Joanne Edwards
    University of Glasgow, Glasgow, United Kingdom
    Clin Cancer Res 9:5271-81. 2003
    ..Hormone resistance remains a significant clinical problem in prostate cancer with few therapeutic options. Research into mechanisms of hormone resistance is essential...
  39. ncbi request reprint Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer
    John M S Bartlett
    Division of Cancer Sciences and Molecular Pathology, University Department of Surgery, Level II Queen Elizabeth Building, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK
    J Pathol 205:522-9. 2005
    ....
  40. ncbi request reprint A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue
    Pauline J Carder
    Department of Histopathology, St James s University Hospital, Leeds, UK
    Breast Cancer Res Treat 92:287-93. 2005
    ..Our results emphasise the need for further studies addressing the role of ERb to be based on a wider consensus on criteria for positivity. Ideally this should be based on calibration against clinical outcome...
  41. ncbi request reprint Detection of HER2 gene amplification by fluorescence in situ hybridization in breast cancer
    John M S Bartlett
    Division of Cancer Sciences and Molecular Pathology, University Department of Surgery, Endocrine Cancer Group and HER2 Reference Laboratory, University of Glasgow, Glasgow Royal Infirmary, UK
    Methods Mol Med 120:309-22. 2006
    ..We describe the use of FISH for HER2 in our own laboratory, based on more than 4000 diagnostic assays, and the optimal approaches to scoring HER2 gene amplification in breast cancer...
  42. ncbi request reprint Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer
    Caroline J Witton
    University Department of Surgery, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
    J Pathol 200:290-7. 2003
    ..The development of HER-targeted agents (eg Herceptin, Iressa), and agents targeted at the downstream signalling pathways, therefore provides new possibilities in the treatment of breast cancer...
  43. ncbi request reprint Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder
    Joanne Edwards
    University Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK
    J Pathol 196:380-5. 2002
    ..Loss of all informative markers, including those residing in the TSC1 region, spanning chromosome 9 was also linked to recurrence...
  44. ncbi request reprint The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells
    Anjali Naresh
    Department of Biochemistry, Tulane University Health Sciences Center, Tulane Cancer Center, LA 70112 2699, USA
    Cancer Res 66:6412-20. 2006
    ..Thus, we propose that ligand-induced mitochondrial accumulation of 4ICD represents a unique mechanism of action for transmembrane receptors, directly coupling a cell surface signal to the tumor cell mitochondrial apoptotic pathway...
  45. pmc An increase in N-Ras expression is associated with development of hormone refractory prostate cancer in a subset of patients
    Pamela Traynor
    University Department of Surgery, Division of Cancer Sciences and Molecular Pathology, Glasgow Royal Infirmary, Glasgow, UK
    Dis Markers 24:157-65. 2008
    ..010) and proliferation index (Ki67, p=0.02). These results suggest that in a subgroup patients N-Ras expression is associated with development of hormone refractory prostate cancer via activation of the MAP kinase cascade...